Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Short Interest Down 12.5% in March

Alaunos Therapeutics, Inc. (NASDAQ:TCRT) was the target of a significant decline in short interest in the month of March. As of March 15th, there was short interest totalling 51,700 shares, a decline of 12.5% from the February 28th total of 59,100 shares. Based on an average daily volume of 16,800 shares, the short-interest ratio is presently 3.1 days. Approximately 3.8% of the shares of the company are sold short.

Alaunos Therapeutics Stock Performance

Alaunos Therapeutics stock opened at $2.16 on Wednesday. The business has a 50 day simple moving average of $1.60 and a 200-day simple moving average of $2.03. Alaunos Therapeutics has a 12 month low of $1.31 and a 12 month high of $18.50.

Alaunos Therapeutics Company Profile

Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers.